Predicting Anticancer Drug Resistance Mediated by Mutations.
Yu-Feng LinJia-Jun LiuYu-Jen ChangChin-Sheng YuWei YiHsien-Yuan LaneChih-Hao LuPublished in: Pharmaceuticals (Basel, Switzerland) (2022)
Cancer drug resistance presents a challenge for precision medicine. Drug-resistant mutations are always emerging. In this study, we explored the relationship between drug-resistant mutations and drug resistance from the perspective of protein structure. By combining data from previously identified drug-resistant mutations and information of protein structure and function, we used machine learning-based methods to build models to predict cancer drug resistance mutations. The performance of our combined model achieved an accuracy of 86%, a Matthews correlation coefficient score of 0.57, and an F1 score of 0.66. We have constructed a fast, reliable method that predicts and investigates cancer drug resistance in a protein structure. Nonetheless, more information is needed concerning drug resistance and, in particular, clarification is needed about the relationships between the drug and the drug resistance mutations in proteins. Highly accurate predictions regarding drug resistance mutations can be helpful for developing new strategies with personalized cancer treatments. Our novel concept, which combines protein structure information, has the potential to elucidate physiological mechanisms of cancer drug resistance.
Keyphrases
- drug resistant
- papillary thyroid
- multidrug resistant
- acinetobacter baumannii
- squamous cell
- machine learning
- healthcare
- emergency department
- lymph node metastasis
- protein protein
- squamous cell carcinoma
- magnetic resonance imaging
- amino acid
- binding protein
- computed tomography
- big data
- cystic fibrosis
- high resolution
- health information
- childhood cancer
- pseudomonas aeruginosa
- magnetic resonance
- climate change
- human health